Kenzora J L, Pérez J E, Bergmann S R, Lange L G
J Clin Invest. 1984 Oct;74(4):1193-203. doi: 10.1172/JCI111528.
Acetyl glyceryl ether of phosphorylcholine (AGEPC), platelet activating factor, is a potent hypotensive agent that may mediate changes in blood pressure during anaphylaxis and may be involved in blood pressure variations of renal origin. This study was designed to characterize the hemodynamic mechanisms responsible for hypotension induced by this recently identified phospholipid. Intravenous administration of AGEPC to anesthetized open-chest dogs (n = 5) produced hemodynamic alterations which, for the purpose of analysis, were divided into three phases based on changes in the mean systemic blood pressure. During phase I (5-30 s) mean systemic blood pressure decreased to levels 5 to 10% below baseline values in association with a rise in cardiac output and a decrease in systemic vascular resistance. Phase II (30-90 s) consisted of a substantial reduction in systemic blood pressure to its nadir, 50% of baseline values, together with a decrease of similar magnitude in cardiac output and a rise in systemic vascular resistance. Phase III (90 s-60 min) exhibited a gradual recovery of mean systemic blood pressure toward normal with a several-fold rise in systemic vascular resistance and a continued low cardiac output. On the right side of the circulation, the predominant effect of AGEPC was a marked transient increase in pulmonary artery pressure in phase I, associated with an elevation of pulmonary resistance during phase II. Diethylcarbamazine blocked virtually all of these hemodynamic changes induced by AGEPC; FPL 55712 substantially blocked the rise in systemic vascular resistance in phase III. These results suggest that leukotrienes may mediate at least some of the hemodynamic effects induced by AGEPC, but further studies will be required when more specific leukotriene blocking agents become available. As assessed during phase III with the end-systolic pressure-dimension relation, myocardial performance itself was diminished. The occurrence of an AGEPC-induced negative inotropic effect was further confirmed in isolated Krebs-perfused guinea pig hearts and isolated blood-perfused rabbit hearts. The results indicate that the mechanism of AGEPC-induced hypotension is complex, affecting both vascular tone and the inotropic state of the myocardium.
磷酰胆碱的乙酰甘油醚(AGEPC),即血小板活化因子,是一种强效的降压剂,可能在过敏反应期间介导血压变化,并且可能参与肾源性血压波动。本研究旨在阐明导致这种最近发现的磷脂引起低血压的血流动力学机制。对麻醉开胸犬(n = 5)静脉注射AGEPC会产生血流动力学改变,为便于分析,根据平均体循环血压变化将其分为三个阶段。在第一阶段(5 - 30秒),平均体循环血压降至比基线值低5%至10%的水平,同时心输出量增加,体循环血管阻力降低。第二阶段(30 - 90秒)包括体循环血压大幅降至最低点,为基线值的50%,同时心输出量下降幅度相似,体循环血管阻力升高。第三阶段(90秒 - 60分钟)表现为平均体循环血压逐渐恢复正常,体循环血管阻力升高数倍,心输出量持续较低。在循环系统右侧,AGEPC的主要作用是在第一阶段肺动脉压显著短暂升高,与第二阶段肺阻力升高相关。乙胺嗪几乎阻断了AGEPC诱导的所有这些血流动力学变化;FPL 55712在很大程度上阻断了第三阶段体循环血管阻力的升高。这些结果表明白三烯可能介导了AGEPC诱导的至少部分血流动力学效应,但当有更特异的白三烯阻断剂时还需要进一步研究。在第三阶段用收缩末期压力 - 维度关系评估时,心肌性能本身降低。在离体Krebs灌注豚鼠心脏和离体血液灌注兔心脏中进一步证实了AGEPC诱导的负性肌力作用的发生。结果表明,AGEPC诱导低血压的机制很复杂,既影响血管张力,也影响心肌的收缩状态。